| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/10/2004 | CA2515798A1 Peptide inhibitors of thrombin as potent anticoagulants |
| 09/10/2004 | CA2515539A1 Liquid formulations of tumor necrosis factor-binding proteins |
| 09/10/2004 | CA2515453A1 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 09/10/2004 | CA2515210A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 09/10/2004 | CA2514781A1 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor |
| 09/10/2004 | CA2514500A1 Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| 09/10/2004 | CA2507527A1 Glycosolated enkephalin agents |
| 09/09/2004 | US20040177391 Cell signaling associated polypeptides for identifying modulators of immune cell interactions and mamalian cellular response; tissue engineering |
| 09/09/2004 | US20040177388 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 09/09/2004 | US20040176749 Insert for the treatment of dry eye |
| 09/09/2004 | US20040176582 Expression vector comprising osteocalcin promoter and nucleotide sequence coding bone morphogenic protein for treatment and prevention of osteoporosis |
| 09/09/2004 | US20040176576 Antibodies against cancer |
| 09/09/2004 | US20040176573 Major histocompatibility complex class I restricted epitope peptide for use in diagnosis, prevention and treament of cell proliferative disorders; antitumor agents |
| 09/09/2004 | US20040176572 Nucleotide sequences coding nervous system polypeptide for use in diagnosis, prevention and treatment of neurodegenerative and psychological disorders |
| 09/09/2004 | US20040176568 Nucleic acids encoding modified parathyroid hormone |
| 09/09/2004 | US20040176567 Bioactive peptides comprising enhanced solubility and reduced aggregatory characteristics for use in diagnosis, prevention and treatment of hypercalaemia, osteoporosis and paget's disease |
| 09/09/2004 | US20040176476 Pharmaceutical composition |
| 09/09/2004 | US20040176461 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 09/09/2004 | US20040176459 Prodrugs of excitatory amino acids |
| 09/09/2004 | US20040176439 coadministration of agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F) |
| 09/09/2004 | US20040176423 HMG-CoA reductase inhibitor with a prostaglandin agonist; treating cartilage defects or disorders or promoting wound healing |
| 09/09/2004 | US20040176402 Controlled-release compositions containing opioid agonist and antagonist |
| 09/09/2004 | US20040176347 Synergistic mixture of astrocyte function-improving agent and tissue plasminogen activator thrombolytic agent |
| 09/09/2004 | US20040176333 2-Mercaptopropionamide derivatives; |
| 09/09/2004 | US20040176314 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
| 09/09/2004 | US20040176307 Method of regulating glucose metabolism, and reagents related thereto |
| 09/09/2004 | US20040176305 Novel compounds useful in pain management |
| 09/09/2004 | US20040176304 arginine-threonine-arginine (RTR) peptide complexed with N-acetyl-Proline-Glycine-Proline; autoimmune diseases: chronic inflammatory bowel diease, rheumatoid arthritis; heart ischemia; Adult respiratory distress syndromes: asthma, emphysema |
| 09/09/2004 | US20040176303 Isolated mollusc amino acid sequence having hydroxyvaline and tryptophan in contiguous residues; modulation of ion levels in cells |
| 09/09/2004 | US20040176302 Methods for inhibiting tumor cell proliferation |
| 09/09/2004 | US20040176301 p21 peptides |
| 09/09/2004 | US20040176300 No hemolytic activity; having leucine in place of tryptophan; synthesizing peptide sequences |
| 09/09/2004 | US20040176298 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 09/09/2004 | US20040176297 Characterizing and predicting responses; identifying most efficient, cost effective and/or convenient treatment regimens; computer profiling |
| 09/09/2004 | US20040176296 Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| 09/09/2004 | US20040176295 Method of promoting bone growth with hyaluronic acid and growth factors |
| 09/09/2004 | US20040176294 Use of thyroid-stimulating hormone to induce lipolysis |
| 09/09/2004 | US20040176293 Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| 09/09/2004 | US20040176292 Methods and compositions for enhancing cognitive function using morphogenic proteins |
| 09/09/2004 | US20040176291 Methods and compositions for soluble CPG15 |
| 09/09/2004 | US20040176290 Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| 09/09/2004 | US20040176288 Treatment and composition for wound healing |
| 09/09/2004 | US20040176287 Employing such as follistatin to increase differentiation of stromal stem cells, myoblast and undifferentiated stromal cells to osteoblast cells |
| 09/09/2004 | US20040176286 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 09/09/2004 | US20040176285 Tip39 polypeptides |
| 09/09/2004 | US20040176284 1,2-Dithio-5,8,11,14,17-pentaazocycloeicosane derivatives |
| 09/09/2004 | US20040176283 Methods and compositions for the design of synthetic vaccines |
| 09/09/2004 | US20040176282 Cellular delivery and activation of polypeptide-nucleic acid complexes |
| 09/09/2004 | US20040176279 Flint glycoforms |
| 09/09/2004 | US20040176277 Methods of treating Pin1 associated disorders |
| 09/09/2004 | US20040176276 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| 09/09/2004 | US20040176275 Pharmaceutical composition for alleviating tissue hypoxia and methods for alleviating tissue hypoxia |
| 09/09/2004 | US20040176272 Uses of integrin alphavbeta3 antagonists |
| 09/09/2004 | US20040175824 Fc fusion proteins of human erythropoietin with high biological activities |
| 09/09/2004 | US20040175817 for in vivo drug screening of anticoagulant agents; enzyme inhibitors |
| 09/09/2004 | US20040175815 kit for treating chronic obstructive pulmonary disease, cancer, and diseases in which cell signaling is defective |
| 09/09/2004 | US20040175813 can be delivered separately or in combination with apoptotic inducing agents via aerosol liposome/transfection/infection methods to treat cellular proliferative diseases and disorders in humans and animals |
| 09/09/2004 | US20040175803 Interferon-alpha induced gene |
| 09/09/2004 | US20040175802 Neutrokine-alpha and Neutrokine-alpha splice variant |
| 09/09/2004 | US20040175801 for drug screening/detecting/treating immune system-related disorders (cancer); genetic engineering |
| 09/09/2004 | US20040175795 Glial derived neurotrophic factor |
| 09/09/2004 | US20040175794 for angiogenic diseases (cancer, cancer metasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling; genetic engineering |
| 09/09/2004 | US20040175791 DcR3 polypeptide, a TNFR homolog |
| 09/09/2004 | US20040175790 for drug screening/diagnostics for detecting and treating immune system-related disorders (cancer); genetic engineering |
| 09/09/2004 | US20040175773 Screening method based on siah-numb interaction |
| 09/09/2004 | US20040175772 for drug screening cancer drugs and tumor activators/suppressors; fluorescence resonance energy transfer; genetic engineering |
| 09/09/2004 | US20040175770 by inducing or mimicking human gene activity causing the degradation of beta -catenin using genetically engineered cells/ animal models |
| 09/09/2004 | US20040175766 Human pyrimidine receptor |
| 09/09/2004 | US20040175758 Novel Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders |
| 09/09/2004 | US20040175757 Low allergenic protein variants |
| 09/09/2004 | US20040175753 HSV-2 type-specific immunoassays using glycoprotein G2 peptides |
| 09/09/2004 | US20040175743 Using cancer marker gene expression profile in peripheral blood mononuclear cells to diagnose cell proliferative disorders and screen efficacy of antitumor agents |
| 09/09/2004 | US20040175740 Using proopiomelanocortin animal mutant to identify modulators of weight and pancreatic disorders |
| 09/09/2004 | US20040175739 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 09/09/2004 | US20040175738 Novel osteopontin derived chemotactic peptides and methods of use |
| 09/09/2004 | US20040175730 Comprises nucleotide sequences coding polypeptide associated with vascular permeability or proliferation of endothelial cells for treating intestinal malabsorption syndrome |
| 09/09/2004 | US20040175721 Antisense nucleotide sequences for use in reducing cell division associated with cell proliferative, skin and autoimmune disorders; RNA interference and microtuble formation |
| 09/09/2004 | US20040175714 Human protooncogene kg-20 and protein encoded therein |
| 09/09/2004 | US20040175703 to be administered by inhalation, infusion, injection, or orally relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference in vitro and in vivo; genetic engineering |
| 09/09/2004 | US20040175700 Using phenotypic, genotypic, physiological and morphogenic variation profiles to diagnose and prognose genetic disorders; genomics |
| 09/09/2004 | US20040175443 Food supplement for increasing lean mass and strength |
| 09/09/2004 | US20040175442 Food supplement for increasing lean mass and strength |
| 09/09/2004 | US20040175419 controlling crystallization parameters of active ingredient to achieve increased compactability; compacting the active ingredient into a tablet |
| 09/09/2004 | US20040175407 Microorganism coating components, coatings, and coated surfaces |
| 09/09/2004 | US20040175401 Drug delivery to the dermis mammal to improve systemic absorption |
| 09/09/2004 | US20040175400 Reducing secretions from the meibomian glands; vision defects |
| 09/09/2004 | US20040175399 Treating hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin or Clostridual neurotoxin |
| 09/09/2004 | US20040175397 Citrullinylarginine dipeptide analogs and their dermatological uses as care and treatment agents |
| 09/09/2004 | US20040175395 Contains connecting disulfide bridge; humanized monoclonal and polyclonal antibodies; diagnostic kits for respiratory syncytial virus |
| 09/09/2004 | US20040175394 Prevention and treatment of amyloidogenic disease |
| 09/09/2004 | US20040175393 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and imunological therapies based thereon |
| 09/09/2004 | US20040175390 Selection of patients with increased responsiveness to botulinum toxin |
| 09/09/2004 | US20040175388 Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial & anti-endotoxin therapeutics |
| 09/09/2004 | US20040175386 Composite powders and skin preparations for external use containing the same |
| 09/09/2004 | US20040175384 Protein kinase C as a target for the treatment of respiratory syncytial virus |
| 09/09/2004 | US20040175383 Administering to mammal a protease inhibitor comprising antitrypsin and/or ilomastat |
| 09/09/2004 | US20040175377 Agent and method for reducing intraocular pressure |
| 09/09/2004 | US20040175375 Downregulation of c-myc by promoting the ubiquitination of FBP, by administering an isolated p38/JTV-1protein or fragment or an isolated nucleic acid encoding said protein; |
| 09/09/2004 | US20040175371 Introducing a biological material into a patient |
| 09/09/2004 | US20040175370 Injecting aqueous solution containing an expression vector comprising desired gene; gene therapy wherein hepatocyte growth factor (HGF) gene is introduced by electroporation into kidney to be transplanted |